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1. Introduction 
Infantile hemangiomas (IHs) belong to a family of lesions called vascular anomalies. 
Vascular anomalies are classified into either vascular tumors or vascular malformations, 
with the IH being the most common vascular tumor, affecting approximately 5% of infants 
(Frieden, Haggstrom et al 2005). Despite their prevalence, the origin and pathogenesis of IHs 
remains poorly understood. 
Clinically, IHs undergo a predictable course of rapid proliferation shortly after birth, 
followed by stabilization and involution throughout childhood. Occasionally, a fibrofatty 
residuum results after involution is complete. Despite its predictable clinical course, the 
regulatory mechanisms throughout different phases are only recently being elucidated 
(Frieden, Haggstrom et al. 2005). 
During the proliferative phase, IH can cause serious morbidity and even mortality. Rapidly 
proliferating hemangiomas can be dangerous as they have potential to ulcerate and bleed. 
While disorganized, IHs are high-flow lesions; occasionally, life-threatening bleeding can 
occur. The location of the IH can also be detrimental. Hemangiomas in the peri-orbital area 
can cause obstructive amblyopia and astigmatism, and airway hemangiomas can cause 
stridor and respiratory distress. Visceral hemangiomas of the liver can cause congestive 
heart failure, hepatomegaly, and anemia; the mortality rate with treatment is significant, up 
to 30% (Arneja and Mulliken, 2010; Bitar et al., 2005; Boon et al., 1996; Ceisler & Blei, 2003; 
Chamlin et al., 2007; Haggstrom et al., 2006a; Schwartz et al., 2006). 
In recent years, PHACE syndrome has been described and characterized. PHACE syndrome 
comprises a constellation of findings including Posterior fossa anomalies, large facial 
Hemangioma, Arterial anomalies, Cardiac abnormalities/aortic Coarctation, and Eye 
anomalies (Frieden et al., 1996). Infants with PHACE syndrome are at increased risk for 
strokes, neurological and cardiac consequences (Burrows et al., 1998; Drolet et al., 2006). 
Another syndrome featuring a large hemangioma over an area with aberrant underlying 
anatomical structures have also been described. PELVIS syndrome describes Perineal 
hemangioma, External genitalia malformations, Lipomyelomeningocele, Vesicorenal 
anomalies, Imperforate anus, and Skin tag (Girard et al., 2006). PHACE and PELVIS 
syndromes suggest that there may be an association between a cutaneous hemangioma and 
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abnormal development of underlying anatomy. Given the existence of these syndromes, as 
well as the predisposition for hemangiomas to occur at the boundaries of developmental 
units near lines of fusion between mesenchymal growth plates (Waner et al., 2003), it seems 
likely that the formation of hemangiomas is closely related to the developmental events that 
take place during embryogenesis. 
There are currently no FDA-approved treatments for IHs, (Acevedo and Cheresh 2008; 
Frieden et al., 2005) although corticosteroids and propanolol have been used with good 
control of problematic IHs. Laboratory studies have suggested that corticosteroids affect the 
vascular endothelial growth factor receptor (VEGFR) pathway (Greenberger et al., 2010), 
and in vitro studies have shown that propanolol can cause apoptosis in endothelial cells 
(Lamy et al., 2010). However, despite these laboratory studies, the exact mechanisms of 
action of these medications on IHs are still unknown. Occasionally, due to either failure of 
medical treatment or the urgency of the potential morbidity and mortality, an infant will 
require urgent surgical intervention (Arneja & Mulliken, 2010; Rabhar et al., 2004). 
In summary, despite the prevalence and potential morbidities and mortalities, treatment of 
IHs relies on pharmacotherapy with poorly understood mechanisms of action, and surgical 
intervention when necessary. Part of the reason treatment for IHs is hampered is due to 
poor understanding of pathogenesis and regulatory signals governing its natural history. 
Therefore, understanding the pathogenesis and regulation of IH growth and involution will 
allow more directed therapy. Moreover, based on associations in PHACE and PELVIS 
syndromes the development of IH may be related to other abnormal anatomic 
developments during embryogenesis. Therefore, IH may be a useful disease model to study 
vascular development and vasculogenesis, as well as give insight to angiogenesis in 
pathologic settings.  
2. Clinical course of IH 
IHs typically affect the skin and occur in 4 to 10% of white infants (Holmdahl et al., 1955), 
with higher incidence in premature infants with low birth weight (Amir et al., 1986), high 
maternal age for the first baby, multiple gestation, complicated pregnancies with pre-
eclampsia or placental abnormalities such as placenta previa. A lower rate is observed in 
dark-skinned children. There is a female predisposition of 3:1 to 5:1. IHs occur most often on 
the head and neck (60%), followed by the trunk (25%) and extremities (15%). Usually, 
cutaneous IHs arise as a single lesion; however, up to 20% of them occur as multiple lesions 
and are also more likely to involve the viscera. IH can develop in the GI tract, pancreas, 
kidney, lung, heart, mediastinum, meninges, and brain. 
By definition, IHs occur after birth. Often, small telangiectasias or discoloration of the skin 
resembling a bruise herald the future development of the IH, but the frank lesion is not 
noticed until several weeks after birth. Congenital hemangiomas are vascular tumors that 
are fully developed at birth and do not have postnatal growth. They either involute rapidly 
(Rapidly Involuting Congenital Hemangiomas, RICH), or will not involute (Non-Involuting 
Congenital Hemangioma, NICH), RICHs and NICHs have a different clinical course from 
IHs and will not be discussed here.  
After their initial appearance, IHs grow quickly over the first 6 to 8 weeks of the infant’s life 
during the proliferative phase. Depending on their location within the dermis, IHs can vary in 
their appearance. Tumors within the dermis are characterized by a bright red coloration, are 
raised, and have a bosselated appearance [Figure 1].  
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Fig. 1. Proliferating hemangioma of the scalp located in the dermis of an infant. Note the 
bright red color, elevation above the level of the normal surrounding skin, and raised, 
bosselated texture. 
Those developing beneath the dermis in the subcuticular layer are usually only slightly 
raised and blue in color [Figure 2]. Growth usually plateaus before a year of age, but there 
are no reliable predictors for how large an IH can become in the first weeks of life. 
 
 
Fig. 2. Proliferating hemangioma located in the subcuticular layer of skin in an infant. Note 
the blue color, less prominent elevation, and smoother skin texture compared to Fig. 1. 
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During the involuting phase, generally from the age of 1 until 5 to 7 years, the IH continues to 
grow, although more slowly and in proportion with the child. Lesions located in the 
superficial dermis become less tense by palpation and a dull purple instead of crimson on 
visual inspection (Mulliken et al., 2000) [Figure 3]. 
 
 
Fig. 3. Involuting hemangioma of the neck in a child. Note the mottled dull red and purple 
coloring compared to Fig. 1, as well as loose, extraneous skin and smoother texture. 
The rate of this regression is difficult to predict, with no apparent links to appearance, 
location, gender, cutaneous depth, or size. However, involution is usually complete by 5 
years of age in 50% of children, 7 years in 70%, and most by 10 to 12 years (Bowers et al., 
1960). 
3. Complications of IH 
The potential morbidity and mortality that can occur as a result of IH is varied and ranges 
from life-threatening bleeding, airway obstruction, or threat to the visual axis during 
proliferation, to scarring and/or disfigurement during and after involution (Maguiness & 
Frieden, 2010). 
Ulceration during proliferation occurs in 5% to 13% of all of IH and can cause significant 
morbidity for affected patients as a result of pain and scarring, as well as anxiety for parents 
[Figure 4].  
Periorbital IHs can cause strabismus and amblyopia from the resultant obstruction of vision, 
and astigmatism can arise from a concomitant pressure or mass effect. If visual compromise 
is suspected, systemic therapy or surgical debulking is indicated. In patients in which 
amblyopia has already developed, the unaffected eye is patched (Ceisler & Blei, 2003; 
Ceisler et al., 2004; Schwartz et al., 2006). 
Other potentially life-threatening complications include airway compromise in subglottic 
hemangiomas and symptomatic liver hemangiomas. Segmental hemangiomas, especially  
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Fig. 4. Ulcerated proliferating hemangioma of the scalp in an infant. 
those located in the mandibular region (classically referred to as having a “beard” 
distribution), have risk up to 63% of an associated airway hemangioma (Orlow et al., 1997). 
All patients with “beard distribution” hemangiomas should have an otolaryngologist 
evalutate him or her by laryngoscopy to rule out an airway hemangioma. Obstructive 
airway hemangiomas present with biphasic stridor. However, they may not be symptomatic 
until 6-8 weeks of life, when the airway hemangioma grows to a critical size that obstructs 
airflow. If the lesions are symptomatic, they may be treated with surgical or laser ablation, 
with or without systemic pharmacotherapy (Rahbar et al., 2004; Saetti et al., 2008).  
Multifocal liver hemangiomas can cause high-output congestive right-sided heart failure, 
while diffuse liver hemangiomas, which fill the entire liver, can cause abdominal 
compartment syndrome and severe hypothyroidism with myxedema coma (Christison-
Lagay et al., 2007). In these cases, aggressive management of the hypothyroidism is 
necessary, systemic or surgical therapy may be required, and rarely even a liver transplant 
is a therapeutic option (Maguiness & Frieden, 2010).  
4. Associated syndromes 
IH is also a prominent feature of two syndromes, PHACES and PELVIS. PHACES is a rare 
neurocutaneous syndrome that can include a constellation of problems such as Posterior 
fossa malformations, Hemangiomas, Arterial anomalies, Coarctation of the aorta and 
cardiac defects, Eye abnormalities, and Sternal cleft or supraumbilical raphe defects. This 
syndrome involves a large facial hemangioma that is segmental in appearance, though the 
IH distribution does not follow dermatomes or Blaschko’s lines (skin lines believed to trace 
the migration of embryonic cells). The pattern of appearance appears to follow 
developmental units, are reproducible, and have been categorized into segments. A segment 
1 distribution involves the frontotemporal forehead and upper eye with extension to the 
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scalp. Segment 2 distribution involves the maxilla, segment 3 is a mandibular or “beard” 
distribution, and the segment 4 distribution is frontonasal, involving a strip of skin from the 
superior forehead along the nose to the philtrum [Figure 5] (Haggstrom et al., 2006b). 
 
 
Fig. 5. Classification of facial segmental hemangioma localization into four areas based on 
observed distribution patterns, segments 1-4. Adapted from Haggstrom et al., 2006b. 
Some of the most common and devastating of the congenital anomalies associated with 
PHACE syndrome are the structural brain and cerebrovascular anomalies (Drolet, et al., 
2006; Metry et al., 2006; Metry et al., 2009). Structural anomalies of the brain parenchyma 
most commonly involve posterior fossa malformations such as Dandy-Walker syndrome, 
though other anomalies such as cerebral hypoplasia, microcephaly, heterotopia, and empty 
sella turcica have also been reported. The arterial anomalies associated with PHACE 
syndrome can manifest as the abnormal origin, abnormal course, hypoplasia, or absence of 
internal carotid or cerebral vasculature on the ipsilateral side of the facial hemangioma. 
Infants have also been reported to have an increased risk of vasculopathy and early stroke 
(Drolet et al., 2006).  
Other conditions in which IH is associated with underlying structural defects include the 
well-described association of segmental lumbosacral hemangiomas with a tethered spinal 
cord, genitourinary anomalies, or both. Additionally, PELVIS syndrome (Perineal 
hemangioma-External genitalia malformations-Lipomyelomeningocele-Vesicorenal 
abnormalities-Imperforate anus-Skin tag) is similar to PHACES in that it too features a large 
hemangioma over an area with underlying structural and vascular aberrencies (Girard, 
Bigorre et al. 2006). In the case of PELVIS syndrome, patients present with a large segmental 
perineal hemangioma not localized to specific dermatomes. It is generally located from the 
sacral area to the thigh or pelvis, but also sometimes found to involve the vaginal wall, 
uterine horn, or fallopian tube. In addition, defects of the spine, genitourinary tract, and 
anus are found. 
5. Treatment 
First line medical treatment for problematic, proliferating IH is currently corticosteroids, 
though propranolol has become a favored mode of treatment recently. Intralesional 
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corticosteroid injections are useful in small, well-localized tumors where the medication will 
be evenly distributed. Systemic treatment is indicated in cases where the IH may cause 
functional impairment or is life-threatening, or the large size of the hemangioma precludes 
local corticosteroid injection. Side effects of corticosteroids include gastrointestinal upset, 
weight gain, hypertension, adrenal suppression, immunosuppression, and growth delay 
(Maguiness & Frieden, 2010). However, most of these effects are reversed on cessation of 
treatment (Boon et al., 1999). Recently, propranolol has been shown to be an effective 
treatment in cases where steroids have been insufficient. Many authors have reported 
positive results in the treatment infants with rapidly proliferating IH, periorbital IH, 
subepiglottic IH, and visceral IH (Buckmiller et al., 2009; Holmes et al., 2010; Léauté-Labrèze 
et al., 2008; Leboulanger et al., 2010; Li et al., 2010; Mazereeuw-Hautier et al., 2010; Sans et 
al., 2009; Tan et al., 2010; Truong et al., 2010). Potential side effects include bradycardia, 
hypotension, and hypoglycemia. In infants with PHACE syndrome, the risk of stroke is 
theoretically increased if propranolol is administered. The efficacy and limitations of 
propanolol on IHs remains to be seen.  
Vincristine is another alternative treatment modality that, while possessing many known 
side effects when used as a chemotherapy agent, has been demonstrated as  an effective 
drug with a good safety profile (Maguiness & Frieden, 2010). In the past, interferon alpha 
(2a or 2b) has also been used in cases where corticosteroids were ineffective. However, due 
to the risk of spastic diplegia in children treated with interferon (Barlow et al., 1998), it is 
currently reserved to cases in which life-threatening IHs have not responded to other forms 
of treatment. 
In summary, while most IHs are asymptomatic and require only monitoring and 
reassurance, there are subsets of IHs that will require aggressive intervention. Current 
medical treatments were discovered serendipitously and their mechanisms of action not 
well understood. Unless the pathogenesis and regulatory signaling mechanisms can be 
delineated, targeted therapy may not be possible. Despite our limited understanding, 
progress has been made in the basic science of IHs. 
6. Pathophysiology of IHs 
6.1 Past studies 
Many descriptive studies have been published regarding hemangiomas. IHs have been 
described as a tumor of endothelial cells, but it is in fact made up of a heterogeneous group 
of cells including endothelial cells, myeloid cells, pericytes, and mast cells (Itinteang et al., 
2011b; Tan et al., 2004; Ritter et al., 2006).  
Histological studies have shown that endothelial cells in IHs are different from normal 
endothelial cells and vascular malformations (Mulliken & Glowacki, 1982). In addition to 
expressing CD31 and von Willebrand factor (vWF), hemangioma endothelial cells 
(HemECs) also express type IV collagenase, vascular endothelial growth factor, and insulin-
like growth factor 2 at high levels during the proliferating phase, and high levels of tissue 
inhibitor of metalloproteinases 1 (TIMP1) during the involuting phase (Takahashi et al., 
1994). E-selectin, urokinase and basic fibroblast growth factor are expressed at high levels in 
both phases. HemECs also express glucose transporter 1 (GLUT1) (North et al., 2000), 
merosin, Lewis Y antigen, and Fc gamma RII (Enjolras et al, 2007) at high levels. In 
particular, GLUT1 is of special interest as it is positive in 100% of IH endothelial cells, and 
not expressed in other infantile vascular tumors such as congenital hemangiomas, tufted 
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angioma, kaposiform hemangioendothelioma, nor vascular malformations. GLUT1 is also 
expressed at high levels in the endothelial cells of barrier tissues such as placental 
endothelial cells and endothelial cells of the blood-brain barrier. The presence of GLUT1 is 
therefore useful as a diagnostic marker to confirm the histological diagnosis of IH (North et 
al., 2001). While these studies give valuable information to the unique appearance, history, 
and histological characteristics of IHs, they gave no insight into their developmental 
pathogenesis or regulatory mechanisms that govern the progression of IHs. 
Due to the fact that endothelial cells in IHs express high levels of GLUT1, similar to 
placental endothelial cells, the “placental theory” of IH origin gained traction. In a study 
comparing the molecular gene expression profile of IHs to multiple different tissues, 
including brain, muscles, skin and placenta, it was found that the molecular profile of IH 
most closely resembled those of placental tissues (Barnés et al., 2005). Moreover, clinical 
observations of an association with IH incidence and exposure to chorionic villus sampling 
further lent credence to this theory (Bauland et al., 2010; Burton et al., 1995; Kaplan et al., 
1990). Nonetheless, although these studies demonstrated an intriguing association between 
the placenta and IH, they have never definitively shown a causal role for the placenta in the 
formation of IH. 
Studies in IHs have been further hampered by the lack of a viable animal model. Many 
studies have claimed to have a mouse model of hemangioma. A transgenic mouse with 
SV40 promoter-driven Polyomavirus Middle T gene demonstrated abnormal vascular 
proliferation with cavernous hemangioma-like structures in the skin, tongue, ear and gastric 
mucosa (Xu et al., 2009). The authors of this paper claimed that this was a model for IH; 
however, these tumors did not involute. Another xenograft model of infantile hemangioma 
onto nude mice did recapitulate the involuting phase, but is not an ideal laboratory model in 
that it has not been demonstrated that these cells can be passaged through mice and 
therefore requires fresh human sample tissue for each experiment (Peng et al., 2005; Tang et 
al., 2007). Furthermore, neither of these models recapitulate the proliferative phase of IH, 
and the authors of these reports did not report evidence of GLUT1 positivity. 
Ritter et al (Ritter et al., 2002; 2003) was one of the first to employ microarrays in an attempt 
to quantify different genes that may be active in different phases of IHs. These studies 
showed that different genes had different expression levels in the proliferating phase versus 
the involuting phase. For instance, insulin-like growth factor 2 was suggested as a putative 
regulator of hemangioma proliferation, as its transcript levels were 10-fold higher than those 
in the involuting hemangiomas. However, these studies did not show causal relationships 
between the array data and IH behavior. 
6.2 Intrinsic theory of hemangiomas 
One important study of the basic science of IHs focused on the intrinsic vs. extrinsic origin 
theory, arguing that infantile hemangiomas arises from an intrinsic somatic mutation in an 
endothelial progenitor cell (Bischoff, 2002). By analyzing X-chromosome inactivation 
patterns using a polymorphism of the X-linked human androgen receptor gene (HUMARA), 
it was found that HemECs display a non-random pattern of X-chromosomal inactivation, 
demonstrating that each HemEC population was clonal and implicating a single progenitor 
cell as their origin. Additionally, non-endothelial cells isolated from hemangiomas did not 
display evidence of clonality, demonstrating that only endothelial cells within IHs are 
clonal. 
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Other studies have shown that the endothelial cells isolated from IHs behave abnormally 
when compared to isolated endothelial cells from foreskin/commercially available dermal 
microvascular endothelial cells. While HemECs display many of the same markers as 
normal endothelial cells such as CD31, vWF, and E-selectin (in response to LPS exposure), 
HemECs proliferate and migrate at a faster rate in vitro in response to treatment with 
exogenous VEGF-A when compared with human dermal microvascular endothelial cells 
(HDMECs) (Boye et al., 2001). A subsequent study showed that HemECs also possess 
properties similar to those of immature endothelial cells, cord blood endothelial progenitor 
cells (cbEPCs). When exposed to the angiogenesis inhibitor endostatin, cbEPCs 
paradoxically exhibited increased adhesion, proliferation and migration in response to a 
VEGF-A gradient, while HDMECs migrated more slowly in response to endostatin 
exposure. Eventually, the response of cbEPCs to the same experiments shifted to mirror that 
of mature endothelial cells as the cells were passaged in culture. HemECs exposed to 
endostatin also demonstrated behavior similar to that of cbEPCs, further demonstrating 
their abnormal behavior when compared with normal endothelial cells (Khan et al., 2006). 
Taken together, these data further support the theory that an anomaly intrinsic to the IH 
gives rise to the lesion. 
Later investigations resulted in the isolation and characterization of a cell called the 
hemangioma stem cell (HemSC) (Khan et al., 2008). These HemSCs were demonstrated to be 
highly proliferative in culture, and capable of differentiating into endothelial, adipocyte, 
chondrocyte, osteocyte, and neuroglial lineages. Furthermore, when mixed with Matrigel 
and subsequently implanted as a subcutaneous Matrigel plug into the backs of nude mice, 
HemSCs formed GLUT1+ endothelial cell-lined functional blood vessels during the first few 
weeks. Four weeks after implantation, however, the Matrigel plugs were instead found to 
contain adipocytes. This was the first valid published animal model of IH, and its 
recapitulation of the natural history of IH gave further credence to the intrinsic theory of IH 
as well as evidence for the new theory of a stem cell as the cellular origin of IHs. 
Some evidence also points to a possible neural crest cell origin for IHs. Waner and 
colleagues were the first to notice that segmental hemangiomas tend to occur at regions of 
embryological fusion (Waner et al., 2003). Several years later, Haggstrom and colleagues 
conducted a larger study, finding that certain segmental facial hemangiomas tend to respect 
embryological boundaries such as the maxillary and mandibular promineces, while others 
did not (Haggstrom et al., 2006b). Using their observations, they grouped the distribution of 
facial hemangiomas into four segments. Given the pattern of distribution of segmental facial 
hemangiomas, these groups also postulated that facial hemangiomas may have a neural 
crest cell origin. Expression of a marker for neural crest stem cells, p75, has also been 
demonstrated in proliferating IH (Itinteang et al., 2010). 
6.3 VEGF pathway 
Different pathways have been suggested as possibly being involved in the pathogenesis and 
development of IHs. The VEGF pathway, as one of the most important signaling molecules 
in normal and pathophysiological angiogenesis, has been the subject of much study. 
VEGFR-1 and VEGFR-2 are both expressed in IH. However, Jinnin et al demonstrated that 
VEGFR-2 signaling is constitutively active in cultured HemECs in the presence of VEGF-A, 
and that this signaling is a result of downregulated VEGFR-1 expression. VEGFR-1 is 
expressed at much lower levels as a result of aberrant increased interaction of a mutated 
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anthrax toxin receptor-1 (ANTXR-1) with b1-integrin and VEGFR-2. The increase in this 
complex formation in HemECs appears to suppress NFAT-promoted transcription of 
VEGFR-1. As both VEGFR-1 and VEGFR-2 proteins bind to VEGF-A, and VEGFR-1 is 
believed to act as a negative regulator of VEGFR-2 signaling through sequestration of VEGF-
A, a decrease in VEGFR-1 expression would lead to constitutive VEGFR-2 signaling. This 
constitutive VEGFR-2 signaling in the presence of VEGF-A helps explain the aberrant 
overgrowth of endothelial cells in IH. 
Studies involving treatment options for IH, such as corticosteroids and propranolol, serve to 
further highlight the importance of the VEGF pathway in IH pathogenesis. Corticosteroids 
have been one of the first-line medical treatments for problematic hemangiomas. 
Greenberger and colleagues demonstrated that dexamethasone treatment of mice implanted 
with HemSCs in a Matrigel plug with led to a dose-dependent inhibition of microvessel 
density in those plugs. Pre-treating HemSCs with dexamethasone, or silencing VEGF-A 
expression in HemSCs using shRNA lentiviral particles, before implantation into mice also 
gave similar results. Furthermore, in vitro administration of dexamethasone to HemSCs 
resulted in a significant decrease in both mRNA transcript and protein expression levels of 
VEGF-A. The authors also showed that VEGF-A expression is present in IHs in the 
proliferating phase, but not in those in the involuting phase, strongly suggesting that early 
expression of VEGF-A by HemSCs has a crucial role in the pathogenesis of IH. (Greenberger 
et al., 2010b). In a subsequent study, the same authors demonstrated that treatment of 
HemSCs with dexamethasone suppresses the activity of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-B). They also showed that direct suppression of NF-B 
activity leads to decreased VEGF-A mRNA and protein expression, suggesting that NF-B 
regulates VEGF-A expression in HemSCs and providing a plausible mechanism explaining 
the clinical effect of corticosteroids on IH (Greenberger et al., 2010a). 
Recently, propranolol has been demonstrated to be an effective drug for the treatment of IH. 
In 2008, Léauté-Labrèze and colleagues reported a dramatic response to propranolol 
treatment in a small cohort of eleven patients with IH (Léauté-Labrèze et al., 2008). 
However, the molecular mechanisms behind this effect are of considerable interest. Recent 
work by Lamy and colleagues in HUVECs has demonstrated that treatment with 
propranolol inhibited proliferation, chemotactic migration, and tube formation in vitro, as 
well as inhibition of VEGF-A-induced tyrosine phosphorylation of VEGFR-2 (Lamy et al., 
2010). While this study demonstrates that propranolol can interfere with some of the 
important steps involved in angiogenesis, shortcomings of this study include lack of in vivo 
data and the fact that none of the experiments were conducted in HemECs and limits the 
application of the group’s conclusions to IHs. More work is needed to elucidate the 
mechanism of action of propranolol on the accelerated involution of IH. 
6.4 TIE/Angiopoietin signaling 
The tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (TIE2)/angiopoietin 
signaling pathway is also another putative regulator of IH pathogenesis. Tie1, Tie2, and 
angiopoietin-2 (Ang2) are strongly expressed in cultured HemECs, with low expression of 
Ang1. Relative to human dermal microvascular endothelial cells (HDMECs), Tie2 mRNA 
and protein expression are increased in HemECs, and HemECs also demonstrate a 
concomitant increase in cellular responsiveness to Ang1 as measured by cellular 
proliferation and migration. Altered regulation of Ang2 has also been observed, with Ang2 
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mRNA expression in HemECs down-regulated in response to serum relative to HDMECs. 
Thus Tie2 and its ligands Ang1 and Ang2 likely have an important role in the pathogenesis 
of hemangioma (Acevedo & Cheresh, 2008; Jinnin et al., 2008; Yu, et al., 2001). 
6.5 Notch signaling 
Recent studies have also focused on the Notch signaling pathway, a highly conserved 
juxtacrine signaling pathway that is involved in cell fate determination during 
embryogenesis. Four Notch receptor genes (Notch1-4) were found to be expressed in IHs, as 
well as 2 Notch ligands, Jagged-1 and Delta-like-4 (Dll-4) (Wu & Kitajewski, 2009). 
Moreover, the Notch expression profile of proliferating hemangiomas is different than that 
of hemangiomas undergoing involution, with involuting hemangiomas demonstrating 
increased expression of Notch4 and Jagged-1 when compared with proliferating 
hemangiomas. HemSCs and HemECs also demonstrate completely different Notch 
expression profiles, with HemSCs expressing higher levels of Notch2 and Notch3, but lower 
levels of Notch1, Notch4, Jagged-1, and Dll-4 compared to HemECs (Wu et al., 2010). These 
data suggest a possible role for Notch signaling in the maintanence of HemSC pluripotency 
and differentiation into HemEC phenotype. 
6.6 Renin-angiotensin system 
Another area of focus on pathogenesis of IH is the renin-angiotensin system (Itinteang et al., 
2011a). Proliferating hemangioma has been demonstrated to express both angiotensin-
converting enzyme (ACE) and angiotensin receptor 2. Blast-like structures isolated from IH 
using an in vitro explant model expressed CD133, CD34, and VEGFR-2, as well as ACE. 
These blast-like structures increased in number following angiotenisin II treatment in a 
dose-response manner. The authors postulate that treatment of IH with propranolol exerts 
its effects at least partially through downregulation of renin activity of the kidney, leading 
to decreased conversion of angiotensinogen to angiotensin I and ultimately to decreased 
angiotensin II levels, thereby decreasing proliferation of IH. While interesting, whether or 
how the renin-angiotensin system contributes to the pathogenesis or development of IHs 
remain to be seen. 
6.7 Tumor endothelial cells 
It has long been known that as tumors develop and increase in size, they recruit blood vessels 
from their host in order to attempt to meet their increased metabolized demands by a process 
termed angiogenesis. The resultant vasculature is abnormal, and characterized by tortuous 
vessels, a disorganized sprouting, vessel leakiness, and loose associations between the vessels’ 
endothelial cells and the basement membrane and pericytes that cover them. While an 
abnormal vasculature is a hallmark of solid tumors, it is only recently that there has been 
evidence suggesting that these blood vessels are composed of endothelial cells that are in and 
of themselves intrinsically abnormal as well. Endothelial cells isolated from human renal cell 
carcinoma have been reported to be more resistant to serum starvation and vincristine-
induced apoptosis when compared to normal endothelial cells, exhibit enhanced Akt 
activation and decreased expression of the tumor suppressor gene PTEN, and do not undergo 
senescence (Bussolati et al., 2003). Murine Lewis lung carcinoma endothelial cells were 
characterized by a comparatively elongated cellular morphology, fewer cell-cell contacts, and 
increased levels of a host of endothelial cell-surface markers (Allport & Weissleder, 2003).  
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Hida and colleagues purified murine endothelial cells from human xenograft models of 
melanoma and liposarcoma and compared them with murine endothelial cells isolated from 
normal murine skin and adipose tissue. They found that endothelial cells isolated from 
tumors were cytogenetically different when compared to normal endothelial cells, 
displaying larger, heterogenous nuclei and aneuploidy that was exacerbated by passage in 
culture. Abnormal multiple centrosomes were also seen, and FISH analysis showed that the 
structural chromosomal aberrations were heterogenous, indicating that the mutations were 
not clonal (Hida et al., 2004). Possible mechanisms for this cytogenetic instability include the 
unique growth factor milieu in the tumor environment causing genetic instability; loss of 
tumor suppressor and checkpoint activity; uptake of human tumor oncogenes by fusion or 
phagocytosis of apoptotic bodies; and transdifferentiation of tumor cells into endothelial 
cells.  
Xiong and colleages isolated endothelial cells from human hepatocellular carcinoma (HCC) 
and adjacent normal tissue, and reported that HCC endothelial cells demonstrate enhanced 
angiogenic activity including enhanced proliferation, resistance to apoptosis in the absence 
of serum, enhanced migration, and enhanced ability to form tubes when implanted into 
Matrigel in the absence of serum. These cells were also relatively resistant to 
chemotherapeutic drugs including adriamycin and 5-fluorouracil, and the antiangiogenic 
drug sorafenib. Tumor endothelial cells share many of the same characteristics of HemECs, 
and further research comparing the similarities and differences between the two cell types 
may give insight both into the origin of IHs and the unique properties of tumor endothelial 
cells (Xiong et al., 2009). 
Interestingly, Dudley and colleagues have recently reported that tumor endothelial cells 
isolated from a transgenic mouse model in which the mice develop prostate 
adenocarcinoma at puberty demonstrate some of the features of mesenchymal stem cells. 
When cultured in vitro and stimulated with osteogenic medium, clonal populations of these 
prostate tumor endothelial cells demonstrated alkaline phosphatase activity, expressed 
bone-specific markers such as osteopontin and osteocalcin, and underwent mineralization. 
These same cells formed cartilage-like tissues when cultured in chondrogenic medium, with 
concomitant upregulation of cartilage-specific genes. However, these tumor endothelial cells 
could not be differentiated to form adipocytes, distinguishing them from normal 
mesenchymal stem cells and HemSCs (Dudley et al., 2008). 
7. Conclusion 
IHs remain poorly understood but may have serious clinical consequences. While many 
details of their pathogenesis and regulatory mechanisms are still not known, they most 
likely originate from a hemangioma stem cell (HemSC) that abnormally differentiate into 
hemangioma endothelial cells (HemEC). These HemECs are different from mature 
endothelial cells in that they retain features of immature endothelial progenitor cells, 
suggesting an abnormality in stem cell differentiation. In addition, many different signaling 
mechanisms have been studied as potential candidates for regulating the transition of IH 
from the proliferating to involuting phase, and from HemSC to HemEC.  
Understanding the mechanisms that regulate IHs will allow directed therapy for affected 
infants. Moreover, IHs also serve as a model of aberrant vasculogenesis and allow for 
greater understanding of vascular development, including the role of the VEGF, Notch, and 
renin-angiotensin signaling pathways. These mechanisms may give insight into 
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hematopoietic differentiation and should be investigated for their potential role in normal 
vasculogenesis. IHs also share many similarities with tumor endothelial cells, and further 
study and comparison with the unique characteristics of tumor endothelial cells could lead 
to new insights into tumor angiogenesis. 
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Tumor angiogenesis is the main process responsible for the formation of new blood vessels that promote
tumor growth and metastasis. This process is driven by potent pro-angiogenic factors that are predominant in
the tumor environment and are produced by both malignant cells and the host cells recruited to the tumor site.
Tumor environment is characterized by the imbalance between pro-angiogenic and anti-angiogenic factors,
which drives the construction of numerous but structurally defective vessels. These poorly perfused and
abnormal vessels significantly contribute to the tumor pathology not only by supporting the expansion of the
tumor mass but also by promoting chronic inflammation, enhancing thrombosis, impeding drug delivery, and
disseminating tumor cells. These problems associated with tumor vasculature continue to attract great
attention of scientists and clinicians interested in advancing the understanding of tumor biology and
development of new drugs. This book complies a series of reviews that cover a broad spectrum of current
topics related to the pathology of tumor blood vessels including mechanisms inducing new vessels,
identification of new targets for inhibition of tumor angiogenesis, and potential clinical use of known and novel
anti-angiogenic therapies. The book provides an update on tumor angiogenesis that could be useful for
oncologists, cancer researchers and biologists with interests in vascular and endothelial cell behavior in the
context of cancer.
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